Seres Therapeutics (NASDAQ:MCRB) had its target price lifted by Chardan Capital from $12.50 to $32.50 in a report issued on Monday morning, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently commented on MCRB. BidaskClub cut shares of Seres Therapeutics from a buy rating to a hold rating in a report on Saturday, July 18th. Oppenheimer boosted their target price on shares of Seres Therapeutics from $7.00 to $30.00 and gave the stock an outperform rating in a research note on Monday. Canaccord Genuity increased their target price on Seres Therapeutics from $11.00 to $38.00 and gave the company a buy rating in a report on Monday. ValuEngine raised Seres Therapeutics from a hold rating to a buy rating in a report on Tuesday. Finally, Zacks Investment Research cut Seres Therapeutics from a buy rating to a sell rating in a research report on Thursday, July 30th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $29.25.

Shares of MCRB stock opened at $23.56 on Monday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -22.65 and a beta of 1.04. Seres Therapeutics has a 52-week low of $2.52 and a 52-week high of $33.00. The company’s 50 day moving average is $5.52 and its 200 day moving average is $4.32.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $6.05 million during the quarter, compared to analyst estimates of $9.67 million. On average, analysts anticipate that Seres Therapeutics will post -0.81 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. PagnatoKarp Partners LLC acquired a new stake in shares of Seres Therapeutics during the 1st quarter valued at $36,000. Royal Bank of Canada raised its position in shares of Seres Therapeutics by 227.2% during the first quarter. Royal Bank of Canada now owns 10,445 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 7,253 shares during the period. Advisor Group Holdings Inc. purchased a new stake in shares of Seres Therapeutics during the first quarter valued at $38,000. BNP Paribas Arbitrage SA boosted its position in shares of Seres Therapeutics by 162.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,351 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 7,025 shares during the period. Finally, FDx Advisors Inc. purchased a new position in Seres Therapeutics in the 2nd quarter worth about $49,000. 93.39% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

See Also: Why Invest in Dividend Kings

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.